The four stages of congestive heart failure, labeled A through D, describe a progression from having risk factors with no heart damage all the way to severe, life-limiting disease. This staging system, developed by the American College of Cardiology and American Heart Association, is designed to be a one-way road: once you move to a higher stage, you don’t move back down, even if your symptoms improve with treatment. That makes early identification and intervention at the lower stages critical.
Five-year survival rates illustrate how dramatically outcomes differ across stages. Community-based research published in Circulation found that 97% of people in Stage A were alive at five years, compared to 96% in Stage B, 75% in Stage C, and just 20% in Stage D.
Stage A: At Risk for Heart Failure
Stage A doesn’t mean you have heart failure. It means you have one or more conditions that significantly raise your chances of developing it. Your heart still looks and functions normally on imaging, and you have no symptoms. The risk factors that place someone in this stage include high blood pressure, coronary artery disease, diabetes, obesity, metabolic syndrome, exposure to drugs that can damage the heart (like certain chemotherapy agents), and a family history of cardiomyopathy.
Because the heart hasn’t changed yet, the entire focus at this stage is controlling those underlying conditions. Managing blood pressure, blood sugar, and cholesterol can prevent progression. For people with diabetes who are also at elevated cardiovascular risk, a newer class of diabetes medication (SGLT2 inhibitors) has been shown to reduce the risk of developing symptomatic heart failure and related hospitalizations. The goal is simple: keep Stage A from becoming Stage B.
Stage B: Pre-Heart Failure
At Stage B, something has changed in the heart’s structure or function, but you still feel fine. There are no symptoms of heart failure. The changes might show up on an echocardiogram as a thickened heart wall, an enlarged chamber, a heart valve that isn’t working properly, or a weakened pumping ability. In some cases, blood tests reveal elevated levels of proteins the heart releases when it’s under strain, even before imaging picks up structural problems. An NT-proBNP level above 125 pg/mL, for example, can signal that the heart is working harder than it should.
Treatment at this stage is more aggressive than Stage A because there’s now measurable heart damage to address. ACE inhibitors are a cornerstone, shown to slow progression to symptomatic heart failure and reduce mortality even in people who feel perfectly healthy. If someone can’t tolerate an ACE inhibitor, an alternative blood pressure medication called an ARB is used instead. These medications improve survival in people with reduced pumping strength regardless of whether symptoms are present, which is why starting them before symptoms appear matters so much.
Stage C: Symptomatic Heart Failure
Stage C is where most people first think of “heart failure.” You have structural heart disease and you’ve experienced symptoms, either currently or in the past. Those symptoms typically include shortness of breath during activity or while lying flat, fatigue, swelling in the legs or ankles, and a reduced ability to exercise. Even if treatment brings your symptoms under control, you remain classified as Stage C permanently. The staging system reflects the underlying disease process, not how you feel on a given day.
This is also where a key measurement called ejection fraction comes into play. Ejection fraction is the percentage of blood your heart pumps out with each beat. A normal range is 55% to 70%. An ejection fraction below 40% typically indicates heart failure with reduced pumping strength (called HFrEF). Some people fall in a mildly reduced range of 41% to 49%, and others have a normal ejection fraction but still have heart failure, a condition known as heart failure with preserved ejection fraction (HFpEF). The distinction matters because treatment strategies differ.
For people with reduced ejection fraction, the 2022 guidelines recommend four foundational types of medication used together: a drug that blocks the hormone system driving fluid retention and heart remodeling (ACE inhibitor, ARB, or a newer combination drug), a beta blocker to slow the heart rate and reduce its workload, a medication that blocks a hormone called aldosterone to prevent scarring and fluid buildup, and an SGLT2 inhibitor. This four-drug combination forms the backbone of treatment and has been shown to extend life and reduce hospitalizations. Lifestyle changes like limiting sodium, staying physically active within your capacity, and monitoring daily weight to catch fluid buildup early are also part of ongoing management.
Stage D: Advanced Heart Failure
Stage D represents heart failure that significantly disrupts daily life despite receiving the best available medication therapy. People at this stage often struggle with basic activities like getting dressed, walking short distances, or eating a full meal. Repeated hospitalizations are common. Shortness of breath may occur even at rest, and fatigue can be constant.
At this point, treatment options extend beyond medications. A mechanical heart pump, known as a left ventricular assist device, can be implanted to help the heart move blood through the body. For some people, this serves as a bridge while waiting for a heart transplant. For others who aren’t transplant candidates, it becomes a long-term therapy. Heart transplantation itself remains an option for selected patients, though the evaluation process is extensive and donor organs are limited. Palliative care, focused on managing symptoms and improving quality of life, becomes an important part of the conversation at this stage as well, sometimes alongside other treatments rather than as a replacement for them.
Stages vs. Functional Classes
You may also hear heart failure described using a separate system called the NYHA functional classification, which runs from Class I to Class IV. This system is different. It describes how limited you are by symptoms right now, and it can change over time. Someone might be Class III (significant limitation during ordinary activity) during a flare-up and improve to Class II (mild limitation) after treatment is adjusted. The ACC/AHA stages, by contrast, only move forward. A person in Stage C who feels great on medication is still Stage C, but their NYHA class might improve from III to I.
Doctors often use both systems together. The stage tells them where you are in the overall disease trajectory, while the functional class tells them how you’re doing day to day. Both pieces of information shape treatment decisions.
How Quickly Heart Failure Progresses
There’s no set timeline for moving from one stage to the next. Some people remain in Stage A or B for decades with proper management of their risk factors. Others progress rapidly, particularly after a major heart attack or if conditions like high blood pressure go untreated for years. The single most important factor in slowing progression is early, consistent treatment. Starting medications at Stage B, before symptoms ever appear, can meaningfully delay or even prevent the transition to Stage C. Once Stage C is reached, sticking with the full recommended medication regimen and monitoring your condition closely gives you the best chance of staying out of Stage D.